A bombshell and a buying opportunity! BioNTech, Bayer, and AI stock NetraMark

NetraMark Holdings: 90% gross margin with AI

The pharmaceutical and biotech industry is currently being challenged by Donald Trump. The US president wants to reduce drug prices and bring production back to the country. This is increasing cost pressure in industry. In order to continue to achieve decent margins, research and development must become more affordable. This is because the development of a prescription drug typically costs between USD 2 billion and USD 3 billion. The latest takeover shows that companies are not letting Trump scare them away and that the US remains attractive. Sanofi, for example, aims to strengthen its US business by acquiring Blueprint Medicines at a cost of around USD 9 billion.

NetraMark is also a takeover candidate. The Company's AI platform helps reduce development costs and bring drugs to market faster. The software gem focuses on supporting clinical trials. This is an exciting niche, as AI companies tend to avoid this area. The reason: the studies are conducted on a few hundred patients. As a result, they provide too few data points for most AI models.

NetraMark has focused on analyzing Phases 2 and 3, where failure rates are particularly high during development. Thanks to a novel topology-based algorithm, NetraMark's AI can work with just a few patients. The AI breaks down patient data sets into subsets.

The NetraMark platform has been successfully used in practice since this year. The Company has already secured a strategic partner in Worldwide Clinical Trials (Worldwide). The globally active contract research organization will offer its clients the NetraAI platform to optimize their studies. A Nasdaq-listed biotech company has also booked support for four studies.

It is, therefore, no surprise that NetraMark CEO George Achilleos is optimistic about the future. In his presentation at the virtual IIF investor conference, he pointed to a gross margin of 90% and a rapidly filling sales pipeline.

https://youtu.be/asqAzE7_2-M?si=TTzMFTPckVqm3LF9

BioNTech receives billion-dollar payments

A bombshell at BioNTech. After the biotech company's shares were collectively punished on Friday and lost significant ground, they jumped by over 10% yesterday.

The reason: a billion-dollar partnership with pharmaceutical company Bristol Myers Squibb (BMS). Both companies announced that they will jointly develop and commercialize BioNTech's bispecific antibody candidate BNT327 in a range of solid tumor types. The aim is to accelerate and expand the development of the clinical product candidate.

BMS will make an upfront payment of USD 1.5 billion to BioNTech and additional uncommitted payments totaling USD 2 billion on annual dates through 2028. BioNTech is also entitled to up to USD 7.6 billion in additional milestone payments for development, approval, and commercialization. BioNTech and BMS will share development and manufacturing costs and worldwide profits equally.

BNT327 is an innovative bispecific antibody targeting the cell surface protein PD-L1 and the signaling protein VEGF-A. The candidate is currently being investigated in several ongoing studies that have already treated more than 1,000 patients.

BioNTech CEO Prof. Ugur Sahin commented: "We believe that BNT327 has the potential to become a fundamental immuno-oncology key therapy that goes beyond checkpoint inhibitors with a single mechanism and can be expanded to multiple solid tumor indications. Our goal is to offer transformative therapy options to patients with high medical needs." BioNTech's focus remains on developing highly effective cross-tumor programs and combination strategies in oncology. BNT327 complements the antibody-drug conjugate programs and mRNA-based immunotherapy candidates.

Bayer: Better than the DAX

Bayer can only dream of such billion-dollar revenues at present. The Company urgently needs to expand its pharmaceutical pipeline. To do this more cost-effectively, a partnership with NetraMark would make sense.

However, Bayer shares have performed surprisingly well this year. They have gained around 30% in 2025 so far – more than the DAX. The stock is currently trading at EUR 25, which is at a strong resistance level.

On the operational front, two minor positive developments were recently reported. The Leverkusen-based company has applied for marketing approval in Japan for the contrast agent Gadoquatrane. This is intended for use in MRI examinations of all parts of the body. What makes it special is that the dose of 0.04 mmol gadolinium per kilogram of body weight is 60% lower than comparable standard agents. Bayer had previously received priority review status from the US Food and Drug Administration (FDA) for the active ingredient sevabertinib. Sevabertinib is intended for the treatment of HER2-mutated non-small cell lung cancer.

NetraMark's AI platform is ahead of its time. The cost of drug development must be reduced. The first customers and partners have been acquired. If scaling up is successful, gross margins of 90% are possible. BioNTech showed yesterday how quickly share prices can sometimes jump. If more positive news comes out of the full oncology pipeline in the coming months, the stock should still have room to rise. At Bayer, the bulls currently have the upper hand. However, the stock is unlikely to really take off until the lawsuits surrounding glyphosate and other products have been settled.